Carbenicillin in patients with cystic fibrosis: clinical pharmacology and therapeutic evaluation.
D000336:Aerosols; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001219:Aspartate Aminotransferases / Q000097:blood; D002648:Child; D003550:Cystic Fibrosis / Q000188:drug therapy*; D004925:Escherichia / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D007709:Klebsiella / Q000187:drug effects; D008171:Lung Diseases / Q000150:complications / Q000188:drug therapy*; D010406:Penicillins / Q000627:therapeutic use*; D011339:Probenecid / Q000008:administration & dosage; D011511:Proteus / Q000187:drug effects; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012141:Respiratory Tract Infections / Q000150:complications / Q000188:drug therapy*; D012705:Serratia / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects
D000336:Aerosols; D000900:Anti-Bacterial Agents; D010406:Penicillins; D001219:Aspartate Aminotransferases; D011339:Probenecid